BioPorto's Strategic Achievement in Q2 2025
In a significant update, BioPorto A/S (CPH:BIOPOR) announced its interim results for the second quarter of 2025, showcasing continued progress towards the execution of its strategic objectives. This period marks not only financial growth but also a notable development in its flagship product, ProNephro AKI.
Financial Growth and Market Expansion
BioPorto reported a robust revenue of DKK 10.6 million for Q2 2025, reflecting a 15% increase from the previous year. This surge is primarily attributed to impressive NGAL sales growth, which climbed by 39% compared to Q2 2024. The momentum in sales extends both within the US and internationally, highlighting the broadening appeal of BioPorto's diagnostic tools in kidney health management.
Strategic Milestones and New Leadership
A key highlight of the second quarter was the receipt of the first purchase order for ProNephro AKI (NGAL), signaling the initial phase of commercialization in the US market. This milestone lays a solid foundation for BioPorto to launch the product effectively, with a target to submit the necessary documentation to the FDA by the end of 2026. To drive such growth, the company has also made significant leadership changes, appointing Jens Due Olsen as Chairman and Carsten Buhl as the new CEO effective September 1.
Clinical Development and Future Guidance
The ongoing US clinical cut-off study for ProNephro AKI is progressing well, nearing its final stages. The company is optimistic about the future, adjusting its full-year guidance for 2025 to reflect better visibility. Total revenue is now expected to be between DKK 45-50 million, while the adjusted EBITDA loss is guided to be between DKK 75-80 million.
Investing in the Future
In April, BioPorto successfully raised DKK 33.5 million through the issuance of 25 million new shares, indicating strong support from existing shareholders. This funding will help propel the company forward, enhancing its research and development capabilities, especially as it focuses on unmet medical needs in kidney diagnostics.
Peter Mørch Eriksen, BioPorto's CEO, expressed enthusiasm over the second quarter developments, stating, "The strong market momentum we are witnessing in the US, combined with the progress in our clinical studies, ensures that we are well-positioned for future growth. Our clearly defined strategy, coupled with new leadership, sets the stage for further advancements in our journey of improving patient management in kidney health."
Frequently Asked Questions
What were BioPorto's key financial highlights for Q2 2025?
BioPorto achieved total revenues of DKK 10.6 million, marking a 15% increase compared to the same period last year, driven primarily by strong NGAL sales performance.
What strategic initiatives did BioPorto achieve in Q2 2025?
Key achievements include receiving the first US purchase order for ProNephro AKI and making significant leadership changes to facilitate growth.
How does BioPorto’s revenue outlook for the full year of 2025 look?
BioPorto expects its total revenue for 2025 to be between DKK 45-50 million and adjusted EBITDA loss between DKK 75-80 million.
What is ProNephro AKI, and why is it significant for BioPorto?
ProNephro AKI is BioPorto's flagship product aimed at improving diagnostic accuracy for Acute Kidney Injury, addressing a significant medical need in patient management.
How is BioPorto handling its clinical studies for ProNephro AKI?
The company is nearing the final phases of its US clinical cut-off study, with plans to submit to the FDA by the end of 2026, indicating strong progress.
